Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Operating Leases (2019 - 2025)

CytomX Therapeutics' Operating Leases history spans 7 years, with the latest figure at $1.4 million for Q2 2025.

  • For Q2 2025, Operating Leases fell 79.06% year-over-year to $1.4 million; the TTM value through Jun 2025 reached $1.4 million, down 79.06%, while the annual FY2024 figure was $4.2 million, 54.82% down from the prior year.
  • Operating Leases reached $1.4 million in Q2 2025 per CTMX's latest filing, down from $2.9 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $20.8 million in Q1 2021 to a low of $1.4 million in Q2 2025.
  • Average Operating Leases over 5 years is $11.9 million, with a median of $12.3 million recorded in 2023.
  • Peak YoY movement for Operating Leases: fell 13.68% in 2021, then tumbled 79.06% in 2025.
  • A 5-year view of Operating Leases shows it stood at $18.1 million in 2021, then fell by 22.6% to $14.0 million in 2022, then plummeted by 32.84% to $9.4 million in 2023, then tumbled by 54.82% to $4.2 million in 2024, then plummeted by 65.99% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Operating Leases are $1.4 million (Q2 2025), $2.9 million (Q1 2025), and $4.2 million (Q4 2024).